Brief: Relay Therapeutics Announces Initial Clinical Data Demonstrating That Rly-2608 Selectively Targets Multiple Pi3kα Mutations

Relay Therapeutics

18/04/2023 17:37

April 18 (Reuters) - Relay Therapeutics Inc  RLAY.O :
    * RELAY THERAPEUTICS ANNOUNCES INITIAL CLINICAL DATA
DEMONSTRATING
THAT RLY-2608 SELECTIVELY TARGETS MULTIPLE PI3KΑ MUTATIONS
    * RELAY THERAPEUTICS INC - MULTIPLE DOSES ACHIEVED SUSTAINED
TARGET EXPOSURE OF ABOUT 80%+ MUTANT PI3KΑ INHIBITION
    * RELAY THERAPEUTICS INC - FAVORABLE INITIAL SAFETY PROFILE
AT
TARGET EXPOSURES
    * RELAY THERAPEUTICS INC - INITIAL ANTI-TUMOR ACTIVITY IN
BREAST
CANCER PATIENTS OBSERVED ACROSS RANGE OF DOSES
    * RELAY THERAPEUTICS INC - CONFIRMED PARTIAL RESPONSE IN
BREAST
CANCER PATIENT WITH 12 PRIOR LINES OF THERAPY
    * RELAY THERAPEUTICS INC - NO GRADE 3 HYPERGLYCEMIA, RASH OR
DIARRHEA OBSERVED AT TARGET EXPOSURES

Further company coverage:  RLAY.O 

 ((Reuters.Briefs@thomsonreuters.com;))